Patents Assigned to Fox Chase Cancer Center
  • Patent number: 7053194
    Abstract: Compositions and methods are provided for identifying novel therapeutic agents for the treatment of cancer and other cellular proliferative disorders.
    Type: Grant
    Filed: March 28, 2002
    Date of Patent: May 30, 2006
    Assignee: Fox Chase Cancer Center
    Inventor: Maureen Murphy
  • Patent number: 6803184
    Abstract: Novel human MOAT genes and their encoded proteins are provided herein. The MRP-related ABC transporters encoded by the disclosed nucleic acid sequences play a pivotal role in the efflux of pharmacologically beneficial reagents from tumor cells. MOAT genes and their encoded protein provide valuable therapeutic targets for the design of anti-cancer agents which inhibit the aberrant growth of malignant cells.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: October 12, 2004
    Assignee: Fox Chase Cancer Center
    Inventors: Gary Kruh, Kun Lee
  • Publication number: 20040111220
    Abstract: The invention includes a computer implemented process to identify at least one pattern and its distribution in a set of data for the purpose of interpreting the data. The process comprises (a) representing a set of data by an original data matrix D residing in a storage device, and; (b) decomposing the set of data into a set of patterns represented by a matrix F and their distribution represented by a matrix A, wherein the matrix F represents the set of patterns needed to describe the data and the matrix A represents the distribution of the set of patterns within the data matrix D, the decomposing comprising performing a Bayesian-based Monte Carlo calculation using at least the data matrix D to determine the matrices A and F, wherein the matrices A and F reconstruct the data matrix D and are more amenable to analysis than the data matrix D. Application of the process to environmental, biological and medical, econometric, and other fields is included in the invention.
    Type: Application
    Filed: December 2, 2003
    Publication date: June 10, 2004
    Applicant: Fox Chase Cancer Center
    Inventors: Michael F. Ochs, Truman R. Brown, Radka Stoyanova, Christos Patriotis
  • Publication number: 20040071696
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Application
    Filed: April 4, 2003
    Publication date: April 15, 2004
    Applicants: The Regents of the University of California, The Fox Chase Cancer Center
    Inventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
  • Patent number: 6699980
    Abstract: Nucleic acid molecules encoding a mismatch endonuclease and its method of use for the detection of mutations in targeted polynucleotide sequences are provided, which facilitate the localization and identification of mutations, mismatches and genetic polymorphisms.
    Type: Grant
    Filed: February 28, 2000
    Date of Patent: March 2, 2004
    Assignee: Fox Chase Cancer Center
    Inventor: Anthony T. Yeung
  • Patent number: 6653074
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein, HEF-1, involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents in methods for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: November 25, 2003
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Geraldine O'Neill, Sarah Fashena
  • Patent number: 6599700
    Abstract: An isolated nucleic acid molecule encoding a human DNA repair enzyme, MED1, is disclosed. Like other mismatch repair genes which are mutated in certain cancers, MED1, encoding nucleic acids, proteins and antibodies thereto may be used to advantage in genetic or cancer screening assays. MED1, which recognizes and cleaves DNA, may also be used for the diagnostic detection of mutations and genetic variants.
    Type: Grant
    Filed: July 31, 2000
    Date of Patent: July 29, 2003
    Assignee: Fox Chase Cancer Center
    Inventor: Alfonso Bellacosa
  • Patent number: 6593098
    Abstract: Novel human BUB genes and their encoded proteins are provided herein. The kinases encoded by the disclosed BUB1A and BUB1B genes play a pivotal role in mitotic checkpoint control. BUB3 is a substrate of these kinases, BUB genes and their encoded proteins provide valuable therapeutic targets for the design of anti-proliferative agents which inhibit the aberrant cellular proliferation observed in tumor cells.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: July 15, 2003
    Assignee: Fox Chase Cancer Center
    Inventors: Timothy Yen, Gordon Chan, Sandra Jablonski
  • Patent number: 6391557
    Abstract: Nucleic acid molecules encoding a mismatch endonuclease and its method of use for the detection of mutations in targeted polynucleotide sequences are provided, which facilitate the localization and identification of mutations, mismatches and genetic polymorphisms.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: May 21, 2002
    Assignee: Fox Chase Cancer Center
    Inventor: Anthony T. Yeung
  • Patent number: 6326150
    Abstract: The present invention provides an improved yeast interaction trap method and reagents for the detection of novel protein-protein interactions. The invention comprises a dual bait system which improves the accuracy of library screens with an immediate selection to eliminate false positives. The dual bait system of the present invention also allows for comparative, simultaneous assessment of interactions between two related members of a protein family or a wild-type versus mutated form of the same protein.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: December 4, 2001
    Assignee: Fox Chase Cancer Center
    Inventors: Erica Golemis, Ilya Serebriiskii, Vladimir Khazak
  • Patent number: 6150511
    Abstract: The present invention provides novel chimeric and fusion proteins useful for facilitating site-specific integration of foreign DNA into a host genome. The chimeric enzymes of the invention comprise a DNA binding moiety fused to a retroviral integrase moiety, preferably at the precise N- or C-terminus. Nucleic acids encoding these fusion proteins can be incorporated into standard retroviral vectors, or can be provided as purified proteins. They are capable of exerting the activities of a wildtype retroviral integrase, including processing retroviral DNA termini, nicking double-stranded DNA and integrating a DNA molecule with processed retroviral termini into another DNA strand.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: November 21, 2000
    Assignee: Fox Chase Cancer Center
    Inventors: Richard A. Katz, Anna Marie Skalka
  • Patent number: 6124434
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an Internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: September 26, 2000
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Susan F. Law, Joanne Estojak
  • Patent number: 6100384
    Abstract: An isolated nucleic acid molecule is provided which encodes a mammalian signal mediator protein involved in regulation of cellular morphological alterations. The encoded protein comprises an amino-terminal SH3 domain, an internal domain containing several SH2 binding motifs, and a carboxy-terminal effector domain that can induce pseudohyphal budding in yeast. The invention also provides the novel signal mediator protein, and antibodies thereto. These biological molecules are useful as research tools and as diagnostic and therapeutic agents for the identification, detection and regulation of complex signaling events leading to morphological, potentially neoplastic, cellular changes.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: August 8, 2000
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Susan F. Law, Joanne Estojak
  • Patent number: 6004958
    Abstract: The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: December 21, 1999
    Assignee: Fox Chase Cancer Center
    Inventors: Truman R. Brown, Francis Kappler, Benjamin Szwergold, Sundeep Lal, Bangying Su
  • Patent number: 5935937
    Abstract: Compositions and methods for the treatment of malignant cells are disclosed, particularly antisense nucleic acid molecules and their use in inhibiting the deregulated cellular proliferation of tumor cells, while not adversely affecting the growth of normal cells.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: August 10, 1999
    Assignee: Fox Chase Cancer Center
    Inventor: Mitchell R. Smith
  • Patent number: 5869650
    Abstract: Dendroamide derivatives are disclosed which are useful in cancer therapy, especially in treating multidrug resistant cells.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: February 9, 1999
    Assignee: Fox Chase Cancer Center
    Inventor: Charles D. Smith
  • Patent number: 5869245
    Abstract: An endonuclease and its method of use for the detection of mutations in targeted polynucleotide sequences are provided, which facilitate the localization and identification of mutations, mismatches and genetic polymorphisms.
    Type: Grant
    Filed: June 5, 1996
    Date of Patent: February 9, 1999
    Assignee: Fox Chase Cancer Center
    Inventor: Anthony T. Yeung
  • Patent number: 5821338
    Abstract: This invention provides a novel gene, OVCA1, isolated from human chromosome 17p13.3. Disruption of the OVCA1 gene is associated with cellular proliferation and tumor development. The OVCA1 gene, along with its encoded protein and antibodies thereto, provides a biological marker for early diagnosis of metastatic disease. The gene also will be useful in gene replacement therapy for treating various forms of cancer.
    Type: Grant
    Filed: June 22, 1995
    Date of Patent: October 13, 1998
    Assignee: Fox Chase Cancer Center
    Inventor: Andrew K. Godwin
  • Patent number: 5801041
    Abstract: This invention provides a novel gene, OVCA1, isolated from human chromosome 17p13.3. Disruption of the OVCA1 gene is associated with cellular proliferation and tumor development. The OVCA1 gene, along with its encoded protein and antibodies thereto, provides a biological marker for early diagnosis of metastatic disease. The gene also will be useful in gene replacement therapy for treating various forms of cancer.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: September 1, 1998
    Assignee: Fox Chase Cancer Center
    Inventor: Andrew K. Godwin
  • Patent number: 5770717
    Abstract: An isolated nucleic acid is provided, which encodes a stress-responsive subunit of mammalian RNA polymerase II, RPB4. In a preferred embodiment, the human RPB4 subunit (hsRPB4) is provided. Also provided are oligonucleotides that specifically hybridize with the nucleic acid, the purified polypeptide encoded by the nucleic acid and antibodies immunologically specific for the polypeptide. These biological molecules are useful as markers of stress-related responses, which may correspond to the occurrence of malignant disease, and as therapeutic agents to modify resistance of a selected cell population to external stress conditions, such as that resulting from treatment of a patient with chemotherapeutic agents.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: June 23, 1998
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Vladimir Khazak, Joanne Estojak